“Biopharmaceuticals Manufacturing Consumables Testing Market Report is set to have rapid growth due to technological advancements and changing or improving regulatory requirements for analysis of raw materials required during biologics manufacturing at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopharmaceuticals Manufacturing Consumables Testing Market Forecast 2019-2029: By Service (Compendial Testing, Laboratory Testing), By Raw Material Type (Excipients, API), Regions and segmental Forecasts.

Effective and successful biopharmaceutical production largely depends on the purity and quality of consumables used during production. With increasing problems related to the quality of new therapies such as poor solubility, increased molecular size and poor absorption properties, there is an increase in attention in the exploration of the various attributes of excipients and other raw materials.

The rapid growth of the biopharmaceutical industry has made it necessary to keep pace with the change or improvement of regulatory requirements for the analysis of raw materials required during organic production. Consequently, manufacturers of final products require the support of the supplier qualification program to validate whether the services offered by the supplier are in compliance with the complementary monographs. This led the segment to support the supplier qualification program based on compendial methods. In addition, technological advances in analytical technologies have provided suppliers with improved capabilities to test proteins, raw materials, cell lines and other consumables used during the production of large molecules. Advances in portable Raman spectroscopy methods are one of the significant developments in this market. Agilent Technologies is one of the companies that offers products based on the principle of Raman spectroscopy.

Leading companies featured in the report include Alcami Corporation; Merck KGaA; Eurofins Scientific; Agilent Technologies; Charles River; Catalent, Inc.; Avomeen Analytical Services; BioSpectra; Pace Analytical Services, LLC and Gibraltar Laboratories

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever